Nvb
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
567 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 31 | 135 | 57 | 6 | 20 | 232 |
| Non-small-cell lung carcinoma | D002289 | — | — | 21 | 80 | 52 | 4 | 17 | 168 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 22 | 69 | 46 | 2 | 12 | 144 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 15 | 11 | 1 | 1 | 29 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 8 | 3 | 1 | — | 13 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | — | — | 1 | — | 1 |
| Meningeal carcinomatosis | D055756 | EFO_1001012 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 8 | 31 | 9 | — | 2 | 46 |
| Neoplasms | D009369 | — | C80 | 23 | 16 | 5 | — | 3 | 38 |
| Hodgkin disease | D006689 | — | C81 | 3 | 17 | 7 | — | 1 | 27 |
| Carcinoma | D002277 | — | C80.0 | 3 | 9 | 6 | — | 2 | 20 |
| Prostatic neoplasms | D011471 | — | C61 | 5 | 10 | 1 | — | 6 | 19 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 8 | 2 | — | — | 13 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 3 | 3 | 7 | — | — | 12 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 7 | 3 | — | 1 | 12 |
| Mesothelioma | D008654 | — | C45 | 1 | 7 | 3 | — | 1 | 12 |
| Sarcoma | D012509 | — | — | 5 | 6 | 1 | — | 1 | 11 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 6 | 3 | — | — | — | 8 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 4 | 3 | — | — | — | 7 |
| B-cell lymphoma | D016393 | — | — | 1 | 5 | — | — | — | 5 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 4 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 3 | — | — | — | 4 |
| Male breast neoplasms | D018567 | — | — | 2 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 1 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 3 | 1 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | — | 3 | — | — | — | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 2 | — | — | 1 | 3 |
Show 43 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | — | — | — | — | 2 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | — | — | — | — | 1 |
| Wilms tumor | D009396 | EFO_0000212 | — | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Vaginal neoplasms | D014625 | — | C52 | 1 | — | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Pheochromocytoma | D010673 | — | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Methylation | D008745 | — | — | — | — | — | — | 1 | 1 |
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Aggressive fibromatosis | D018222 | — | D48.11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | — |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use